Mayo Clinic researchers study medications and treatments for people with kidney transplants, including new medications (immunosuppressive medications) to keep your body from rejecting your kidney transplant. Researchers also study new or improved ways to lower antibody levels in your blood to reduce rejection of a donor kidney and improve outcomes when the match between a donor and recipient is suboptimal (positive crossmatch kidney transplant or ABO incompatible kidney transplant).
Researchers are studying new ways to use immunosuppressive medications, including tacrolimus (Prograf, Protopic), sirolimus (Rapamune) and steroid-free immunosuppression medication options, to help reduce side effects and complications for people with kidney transplants.
Also, researchers are testing and developing potential new immunosuppressive medication options to prevent or treat rejection, including eculizumab, alefacept, voclosporin, sotrastaurin, tofacitinib, bortezomib and others. For example, belatacept (Nulojix) has now been approved by the Food and Drug Administration as a new immunosuppressant medication option for people with kidney transplants.
Mayo Clinic transplant staff can answer your questions about the transplant process and post-transplant life.
Read about transplant clinical trials underway at Mayo Clinic Transplant Center.
Mayo Clinic researchers study new surgical procedures, develop new anti-rejection and other medications, and put into practice ways to improve care during and after transplant.